Purdue Pharma's Novel Dual-Mechanism Drug Tinostamustine Enters Phase 2/3 Trial for Glioblastoma
Key Insights
Purdue Pharma and GCAR (search) have initiated enrollment of tinostamustine in the GBM AGILE adaptive platform trial for newly diagnosed and recurrent glioblastoma (search) patients.
Tinostamustine represents a first-in-class therapeutic combining DNA (search) alkylating activity and HDAC (search) inhibition to target both genomic instability and epigenetic dysregulation in aggressive brain cancers.
The GBM AGILE trial's innovative design enables multiple therapies to be evaluated simultaneously against a shared control arm, potentially supporting future FDA registration.
The Global Coalition for Adaptive Research (search) (GCAR (search)) and Purdue Pharma L.P. have announced the activation of investigational tinostamustine in GBM AGILE, a pioneering international adaptive platform trial designed to accelerate the identification of effective treatments for glioblastoma (search). The drug will be evaluated for adult patients with newly diagnosed glioblastoma across GBM AGILE sites, with additional study in a cohort of patients with recurrent disease at select locations.
Glioblastoma (search) represents the most common and aggressive form of primary brain cancer (search), with treatment options remaining limited and patient outcomes showing minimal improvement over the past several decades. The disease continues to pose significant challenges for clinicians and patients alike, driving the urgent need for innovative therapeutic approaches.
Novel Dual-Mechanism Approach
Tinostamustine distinguishes itself as a first-in-class, new chemical entity that combines two potentially synergistic mechanisms of action. The drug features bifunctional DNA (search) alkylating activity, which triggers apoptosis, alongside pan histone deacetylase (search) inhibition (HDAC (search) inhibition). Beyond improving alkylating agent access to DNA, HDAC inhibition has been shown to disrupt oncogenic signaling pathways and enhance immune recognition of tumor cells.
This dual mechanism may prove particularly relevant in aggressive and treatment-resistant cancers like glioblastoma (search), where both genomic instability and epigenetic dysregulation drive disease progression. Tinostamustine has the potential to serve as a first-line treatment and is being investigated in patients with newly diagnosed glioblastoma as an adjuvant therapy following standard treatment with surgery, chemotherapy and radiation.
Adaptive Platform Trial Design
GBM AGILE operates as a seamless phase 2/3 study conducted under a master protocol, enabling multiple therapies or combinations of therapies from different pharmaceutical companies to be evaluated simultaneously against a shared control arm. With its innovative design and efficient operational infrastructure, data from GBM AGILE can potentially be used as the foundation for a new drug application (NDA) and registrations to the U.S. FDA and other health authorities.
Since its launch in 2019, GBM AGILE has evaluated multiple investigational therapies and has screened over 2,600 patients at approximately 60 trial locations in six countries. The trial represents a significant advancement in clinical research methodology for this challenging indication.
Expert Perspectives
Dr. John de Groot, Neuro-Oncology Division Chief at the University of California, San Francisco, and Dr. Shiao-Pei Weathers, Brain Tumor Section Chief at the University of Texas MD Anderson Cancer Center, are serving as the Principal Investigators for tinostamustine's evaluation in GBM AGILE. Dr. Timothy Cloughesy, Director of the Neuro-Oncology Program at UCLA, serves as the Global Principal Investigator for the overall study.
"Glioblastoma (search) remains one of the most aggressive and difficult-to-treat cancers we encounter in clinical practice," said Dr. de Groot. "There is a pressing need to explore novel mechanisms of action in well-designed studies. GBM AGILE's adaptive platform design allows us to rigorously evaluate promising therapies like tinostamustine while generating high-quality data efficiently."
Dr. Weathers emphasized the importance of providing patients access to innovative investigational therapies. "Despite advances in oncology, outcomes for patients with glioblastoma (search) remain poor," she noted. "Participating in a global study like GBM AGILE gives patients access to innovative investigational therapies that would otherwise not be available outside of a clinical trial."
Development Strategy
Dr. Julie Ducharme, Vice President and Chief Scientific Officer at Purdue, expressed optimism about the trial initiation. "We are pleased to initiate the evaluation of tinostamustine in GBM AGILE, an innovative adaptive trial designed to efficiently determine whether promising therapies like tinostamustine can provide meaningful benefit to patients with glioblastoma (search)," she said. "Encouraging findings from prior clinical studies support continued investigation, and we look forward to advancing the development of tinostamustine for this devastating disease, where significant unmet need remains."
Dr. Meredith Buxton, CEO and President of GCAR (search), highlighted the collaborative approach. "At GCAR, our mission is to rethink how therapies are developed for aggressive cancers like glioblastoma (search)," she said. "Through master protocols and adaptive platform trials, we aim to streamline evaluation and accelerate decision-making. Our collaboration to evaluate tinostamustine represents an important step toward rapidly advancing new treatments in GBM AGILE and bringing new hope to patients."
The activation of tinostamustine in GBM AGILE represents the culmination of years of scientific development and partnership between GCAR (search) and Purdue Pharma, underscoring the companies' commitment to addressing one of oncology's most challenging diseases through innovative clinical trial design and novel therapeutic mechanisms.